Nicholas James

Citado por

	Total	Desde 2019
Citas	39442	21431
Índice h	82	59
Índice i10	252	180

4800

2400

1200

3600

200320042005200620072008200920102011201220132014201520162017201820192020202120222023202498 154 430 415 566 575 562 713 881 1031 1149 1484 1740 2069 2305 2787 3095 3343 4337 4712 4352 1510

Acceso público

Ver todo

180 artículos

14 artículos

disponibles

no disponibles

Basado en requisitos de financiación

Coautores

Matthew R SydesMRC Clinical Trials Unit at UCL, Institute of Clinical Trials and Methodology, University CollegeDirección de correo verificada de ucl.ac.uk
SYED A HUSSAINProfessor of Medical Oncology, University of SheffieldDirección de correo verificada de sheffield.ac.uk
Richard BryanUniversity of BirminghamDirección de correo verificada de bham.ac.uk
Maurice ZeegersProfessorDirección de correo verificada de maastrichtuniversity.nl
K K ChengUniversity of BirminghamDirección de correo verificada de bham.ac.uk
Robert HuddartInstitution of Cancer ResearchDirección de correo verificada de icr.ac.uk
Emma HallProfessor of Oncology Clinical Trials, The Institute of Cancer ResearchDirección de correo verificada de icr.ac.uk
Gerhardt AttardUniversity College London Cancer InstituteDirección de correo verificada de ucl.ac.uk
Joe M. O'SullivanProfessor of Radiation Oncology., Queen's University BelfastDirección de correo verificada de qub.ac.uk
douglas g warduniversity of birminghamDirección de correo verificada de bham.ac.uk
Johann de BonoInstitute of Cancer ResearchDirección de correo verificada de icr.ac.uk
Christopher SweeneyUniversity of AdelaideDirección de correo verificada de adelaide.edu.au
Sarah PirrieCRUK Clinical Trials Unit, University of BirminghamDirección de correo verificada de bham.ac.uk
Prash PatelUniversity College London Hospitals (UCLH)Dirección de correo verificada de bham.ac.uk
Peter HoskinProfessor of Clinical Oncology, University of ManchesterDirección de correo verificada de nhs.net
Lawrence S. YoungUniversity of WarwickDirección de correo verificada de warwick.ac.uk
Oliver SartorTulane UniversityDirección de correo verificada de tulane.edu
Lucinda BillinghamUniversity of BirminghamDirección de correo verificada de bham.ac.uk
Cora N. SternbergClinical Director, Englander Institute for Precision Medicine, Professor of Medicine, Weill CornellDirección de correo verificada de med.cornell.edu
Bertrand TOMBALCliniques universitaires Saint LucDirección de correo verificada de uclouvain.be

Seguir

Nicholas James

Professor of Prostate and Bladder Cancer Research, Institute of Cancer Research

Dirección de correo verificada de icr.ac.uk - Página principal

oncology


Título Ordenar por citas Ordenar por año Ordenar por título	Citado por Citado por	Año
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer IF Tannock, R De Wit, WR Berry, J Horti, A Pluzanska, KN Chi, S Oudard, ... New England Journal of Medicine 351 (15), 1502-1512, 2004	7215	2004
Alpha emitter radium-223 and survival in metastatic prostate cancer C Parker, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, SD Fosså, ... New England Journal of Medicine 369 (3), 213-223, 2013	3659	2013
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage … ND James, MR Sydes, NW Clarke, MD Mason, DP Dearnaley, MR Spears, ... The Lancet 387 (10024), 1163-1177, 2016	2070	2016
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group Lancet (London, England) 397 (10285), 1637, 2021	1838*	2021
Abiraterone for prostate cancer not previously treated with hormone therapy ND James, JS de Bono, MR Spears, NW Clarke, MD Mason, ... New England Journal of Medicine 377 (4), 338-351, 2017	1730	2017
Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial CC Parker, ND James, CD Brawley, NW Clarke, AP Hoyle, A Ali, ... The Lancet 392 (10162), 2353-2366, 2018	1069	2018
Radiotherapy with or without chemotherapy in muscle-invasive bladder cancer ND James, SA Hussain, E Hall, P Jenkins, J Tremlett, C Rawlings, ... New England Journal of Medicine 366 (16), 1477-1488, 2012	998	2012
A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor JCC Hu, RS Coffin, CJ Davis, NJ Graham, N Groves, PJ Guest, ... Clinical cancer research 12 (22), 6737-6747, 2006	654	2006
Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind … O Sartor, R Coleman, S Nilsson, D Heinrich, SI Helle, JM O'Sullivan, ... The Lancet Oncology 15 (7), 738-746, 2014	552	2014
Survival with newly diagnosed metastatic prostate cancer in the “docetaxel era”: data from 917 patients in the control arm of the STAMPEDE trial (MRC PR08, CRUK/06/019) ND James, MR Spears, NW Clarke, DP Dearnaley, JS De Bono, J Gale, ... European urology 67 (6), 1028-1038, 2015	509	2015
Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial RECOVERY Collaborative Group, PW Horby, M Mafham, L Peto, ... Medrxiv, 2021.06. 15.21258542, 2021	480*	2021
Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of … CL Vale, S Burdett, LHM Rydzewska, L Albiges, NW Clarke, D Fisher, ... The lancet oncology 17 (2), 243-256, 2016	479	2016
Required growth facilitators propel axon regeneration across complete spinal cord injury MA Anderson, TM O’Shea, JE Burda, Y Ao, SL Barlatey, AM Bernstein, ... Nature 561 (7723), 396-400, 2018	434	2018
Confronting false discoveries in single-cell differential expression JW Squair, M Gautier, C Kathe, MA Anderson, ND James, TH Hutson, ... Nature communications 12 (1), 5692, 2021	388	2021
Critical analysis of bladder sparing with trimodal therapy in muscle-invasive bladder cancer: a systematic review G Ploussard, S Daneshmand, JA Efstathiou, HW Herr, ND James, ... European urology 66 (1), 120-137, 2014	384	2014
Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior … CN Sternberg, DP Petrylak, O Sartor, JA Witjes, T Demkow, JM Ferrero, ... Journal of clinical oncology 27 (32), 5431, 2009	383	2009
Management of patients with advanced prostate cancer: recommendations of the St Gallen Advanced Prostate Cancer Consensus Conference (APCCC) 2015 S Gillessen, A Omlin, G Attard, JS De Bono, E Efstathiou, K Fizazi, ... Annals of Oncology 26 (8), 1589-1604, 2015	376	2015
Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial NW Clarke, A Ali, FC Ingleby, A Hoyle, CL Amos, G Attard, CD Brawley, ... Annals of Oncology 30 (12), 1992-2003, 2019	356	2019
Use of prenatal chromosomal microarray: prospective cohort study and systematic review and meta‐analysis SC Hillman, DJ McMullan, G Hall, FS Togneri, N James, EJ Maher, ... Ultrasound in Obstetrics & Gynecology 41 (6), 610-620, 2013	322	2013
Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial CC Parker, NW Clarke, AD Cook, HG Kynaston, PM Petersen, C Catton, ... The Lancet 396 (10260), 1413-1421, 2020	286	2020

El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.

Artículos 1–20

Citas por año

Citas duplicadas

Citas combinadas

Añadir coautoresCoautores

Seguir

Citado por

Coautores